Akademik Veri Yönetim Sistemi
Annals of Vascular Surgery, cilt.120, ss.260-269, 2025 (SCI-Expanded)
Background: Restenosis of the superficial femoral artery (SFA) following endovascular treatment remains a significant clinical challenge in peripheral artery disease (PAD). This study evaluates the prognostic value of the Aggregate Index of Systemic Inflammation (AISI) as a biomarker for predicting restenosis risk in SFA lesions. Methods: In a retrospective cohort study, 632 patients undergoing endovascular interventions for symptomatic PAD were analyzed. AISI was calculated as: (neutrophils × platelets × monocytes)/lymphocytes. Patients were divided into 2 groups as those who developed restenosis and those who did not develop restenosis. Multivariate logistic regression and Cox proportional hazards models were used to identify independent predictors of restenosis. Results: Among 632 patients, 142 developed restenosis. The median AISI was significantly higher in the restenosis group compared to the nonrestenosis group (909.28 vs. 516.59, P < 0.001). Patients with high AISI demonstrated a 2.13-fold increased risk of restenosis (hazard ratio: 2.133, 95% confidence interval: 1.508–3.017, P < 0.001) and a shorter time to restenosis (median: 6 months vs. 12 months). Smoking, presence of prior intervention, intervention types, and stent-graft use were also associated with an elevated risk of restenosis. Receiver operating characteristic analysis identified an AISI cutoff value of 489.64 (sensitivity: 57%, specificity: 56%, area under the curve: 0.623). Conclusion: AISI is a promising inflammatory biomarker for predicting the risk of restenosis in PAD patients undergoing endovascular treatment of the SFA. Incorporating AISI into clinical practice could enhance risk stratification and guide personalized management strategies. Prospective studies are needed to confirm these findings and further investigate the mechanistic role of systemic inflammation in restenosis development.